EUVIMEDEUVIMED entdecken
Crossref

Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants

Mandana Kashaki, Elahe Norouzi, Arezoo Aminyan Daryasari, Mahsa Maleki, Fahimeh Farhanian

Advancements in Life Sciences · 30.06.2023 · 10 (2) · 304

DOI: 10.62940/als.v10i2.1856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advancements in Life Sciences, online erschienen am 30.06.2023. Verfasst von Mandana Kashaki und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Premature birth is an important issue in developing and developed countries. The purpose of this study is to investigate the effect of budesonide and surfactant in the treatment of respiratory distress syndrome and the prevention of bronchopulmonary dysplasia (BPD).

Methods

In a randomized clinical trial study, 296 premature babies with a gestational age of less than 37 weeks and weigh below 1500 grams admitted to Shahid Akbarabadi Hospital in Tehran (Iran) who were hospitalized with a diagnosis of respiratory distress syndrome and needed treatment with surfactant were included in the study. In one group (surfactant), 4 cc/kg surfactant (Braksurf) was injected intratracheally, and in the other group (surfactant + budesonide), in addition to surfactant (Braksurf), 0.25 mg/kg of budesonide was prescribed along with intratracheal surfactant. Descriptive statistics including Kaplan-Meier, Chi-square test and t-Student test were used for data analysis.

Result

In infants who were administered budesonide with surfactant through a tracheal tube, the duration of mechanical ventilation, the duration of high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) and the need to receive peripheral equipment or through channel The nose was significantly less than the babies who received only surfactant. In the surfactant group, 13 infants (8.7%) and in the surfactant + budesonide group, 4 infants (2.7%) had bronchopulmonary dysplasia.

Conclusion

The use of the combination of surfactant (Braksurf) with budesonide compared to surfactant alone in the treatment of premature infants significantly reduced the need for respiratory support and the need for intubation and duration of hospitalization and bronchopulmonary dysplasia.Keywords: Budesonide; Surfactant; Premature babies; Respiratory Distress Syndrome; Bronchopulmonary dysplasia

Zitieren

APA

Kashaki, M., Norouzi, E., Daryasari, A. A., Maleki, M., & Farhanian, F. (2023). Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants. Advancements in Life Sciences, 10(2), 304. https://doi.org/10.62940/als.v10i2.1856

Vancouver

Kashaki M, Norouzi E, Daryasari AA, Maleki M, Farhanian F. Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants. Advancements in Life Sciences. 2023;10(2):304. doi:10.62940/als.v10i2.1856

BibTeX
@article{Kashaki2023,
  author = {Kashaki, Mandana and Norouzi, Elahe and Daryasari, Arezoo Aminyan and Maleki, Mahsa and Farhanian, Fahimeh},
  title = {Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants},
  journal = {Advancements in Life Sciences},
  year = {2023},
  volume = {10},
  number = {2},
  pages = {304},
  doi = {10.62940/als.v10i2.1856}
}
Kostenlos starten →